Uric Acid Levels Might be A Prognostic Indicator For Survival in Patients Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation. Single-Center Experience

Uric acid (UA) is an abundant aqueous antioxidant that accounts for almost two-thirds of all free- free-radical-scavenging activity in human serum. It is released from injured cells during conditioning for allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study aimed to evaluate the prognostic impact of pretransplantation uric acid levels on survival and mortality in allo-HSCT patients. We retrospectively analyzed 267 patients with hematologic diseases undergoing allo-HSCT. UA levels on the day of allo-HSCT (day 0) were recorded. Patients were divided into 2 groups; patients with pretransplant UA lower than ≤4.4 mg/dl and higher than >4.4 mg/dl. 153 (57.3%) of the patients were male, while 114 (42.7%) were female. The median age was 31 years (range 13-66). Patients with serum UA levels ≤4.4 mg/dl experienced significantly inferior overall survival (OS) and disease-free survival (DFS) when compared to patients with serum UA levels >4.4 mg/dl (p=0.032 and p=0.045, respectively). Our findings indicated that low serum UA levels before transplantation were associated with poor survival in patients who underwent allo-HSCT. In the future, uric acid may be considered a potential prognostic marker in allo-HSCT as more research is conducted into underlying mechanisms, such as decreased antioxidative capacity in hypouricemia.